HSINCHU, Taiwan and WUHAN, China, Dec. 20, 2017 /PRNewswire/ -- JHL Biotech (Stock Code: 6540.TWO) announced today that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function...
from PR Newswire: //www.prnewswire.co.uk/news-releases/jhl-biotech-submits-clinical-trial-application-in-europe-for-proposed-dornase-alfa-biosimilar-to-665481443.html
No comments:
Post a Comment